Western blot

Mammalian Polyclonal IgG Antibody Global Market Report 2023: Growing Prevalence of Standard Laboratory Tests Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 16, 2023
Biotechnology, Science, Health, Research, Neoplasm, Syphilis, Prevalence, Antibody, Immunoelectrophoresis, Organization, Epitope, Immunoglobulin G, Conditional sentence, University, Human, COVID-19, IHC, AIDS, Flow cytometry, Immunohistochemistry, Cancer, Hospital, CVD, Government, Anemia, Growth, GSK plc, Viral, Government agency, Acceleration, ELISA, Lyme disease, Mouse, Plasma, Application, Biomarker, Agilent Technologies, USD, Region, Diagnosis, CDC, Western blot, Rabbit, Serum, Autoimmunity, SARS-CoV-2, State, Investment, GenScript Biotech, Animal, Disease, Chip, Incidence, Diabetes, Fine chemical, Pharmaceutical industry, Vaccine, Immunoprecipitation

The "Mammalian Polyclonal IgG Antibody Market by Type, by Product, by Application, by End-user, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Mammalian Polyclonal IgG Antibody Market by Type, by Product, by Application, by End-user, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
  • The mammalian polyclonal IgG antibody market size is estimated to be USD 1,347.4 million in 2022 and is expected to witness a CAGR of 5.28% during the forecast period 2023-2033.
  • Furthermore, growing prevalence of standard laboratory tests, government investment, acceleration in institutional and academic research, and affordability of supporting equipment and technology are other factors supporting the market growth.
  • Growing prevalence of standard laboratory tests such as microarray assays, western blot analysis, immunohistochemical, and cell imaging is predicted to propel the mammalian polyclonal IgG antibody market growth during the forecast period.

Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting

Retrieved on: 
Friday, February 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Safety, Therapy, Allergy, Half-life, Prekallikrein, Plasma kallikrein, Hereditary angioedema, Protease, Plasma, American Academy of Allergy, Asthma, and Immunology, HAE, ADAS, Asthma, American Academy, Pharmaceutical industry, Western blot, Chromogen

Additionally, there were no clinically significant changes in laboratory assessments, and there were no treatment-emergent anti-drug antibodies (ADAs) detected.

Key Points: 
  • Additionally, there were no clinically significant changes in laboratory assessments, and there were no treatment-emergent anti-drug antibodies (ADAs) detected.
  • At Day 84, mean concentrations remained above the threshold for potential efficacy after a single 300 mg subcutaneous dose.
  • Initial results from a Phase 1a trial in healthy subjects support STAR-0215’s target profile: a long-acting preventative therapy, best-in-class PK profile, and dosing once every three months or less frequently.
  • The Phase 1b/2 ALPHA-STAR trial evaluating STAR-0215 in people living with HAE is ongoing, with initial results from single and multiple dose cohorts expected in mid-2024.

Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle

Retrieved on: 
Monday, October 17, 2022
U.S. Securities and Exchange Commission, Congress, HSV, ESGCT, Disease, Efficiency, IND, Therapeutic index, Animal, European Society of Gene and Cell Therapy, Family, NOS1, Solid, Patient, Mitoxantrone, Gene, Cell, Neuraminidase, Security (finance), Private Securities Litigation Reform Act, Goal, Duchenne muscular dystrophy, Company, Mutation, AAV, Muscle, Teniposide, Liver, Etoposide, Safety, GLOBE, Brain, Insulin, Western blot, FDA, Poster, Skeletal muscle, Vaccine, Pharmaceutical industry, Duchenne

CHARLESTOWN, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences, a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), presented additional data characterizing AAV-SLB101, a novel adeno-associated virus (AAV) vector designed for improved transduction efficiency and biodistribution to muscle cells. AAV-SLB101 is the capsid used in SGT-003, Solid’s next-generation gene therapy for Duchenne. The data were presented in a poster (P011) at the European Society of Gene and Cell Therapy (ESGCT) 29th Congress, in Edinburgh, Scotland, October 11-14.

Key Points: 
  • In studies in wild-type mice, the mdx mouse model of Duchenne (DMDmdx), and non-human primates (NHPs) AAV-SLB101 demonstrated superior transduction efficiency compared with AAV9.
  • In DMDmdx mice, microdystrophin protein expression by western blot and immunofluorescence was also significantly higher with AAV-SLB101 compared with AAV9.
  • Solid also presented new SGT-003 non-clinical data which reinforced previous comparative analyses that have demonstrated increased microdystrophin expression using the novel muscle-tropic capsid AAV-SLB101 compared to AAV9.
  • The identification of this binding partner enables the rational design of additional capsids that may have even greater targeting to muscle tissue.

Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Tuesday, July 5, 2022
FDA, Diaphragm, Muscle, Patient, LinkedIn, Duchenne muscular dystrophy, Heart, Achievement, GLOBE, Facioscapulohumeral muscular dystrophy, COVID-19, DMD, Company, Degenerative disease, Disease, Securities and Exchange Commission (Philippines), Terminology, Mortality, Form 10-Q, Pharmacokinetics, PMO, Exon, Food, Partnership, Therapy, Duchenne, Dystrophin, Clinical trial, IND, Cardiac muscle, Myopathy, DM1, Nasdaq, FSHD, SEC, Western blot, MAD, Private Securities Litigation Reform Act, Time, Outline, Safety, Twitter, DYN, FORCE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Transferrin, Security (finance), Pharmaceutical industry, Dyne, Facebook

WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared its Investigational New Drug (IND) application to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51. The Company expects to begin dosing patients in a Phase 1/2 clinical trial evaluating DYNE-251 in mid-2022.

Key Points: 
  • The clearance of our first IND is an important achievement for Dyne, and we appreciate the partnership with the FDA throughout this process.
  • We believe we are well-positioned to deliver on our commitment of initiating dosing in both of our DMD and DM1 programs in mid-2022.
  • Dyne plans to evaluate DYNE-251 in a global, randomized, placebo controlled, multiple ascending dose (MAD) clinical trial with a long-term extension study.
  • DYNE-251 is Dynes product candidate being developed for people living with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

Aviva Systems Biology Launches AvivaBlot ECL Reagents for Western Blot

Retrieved on: 
Monday, April 11, 2022
IHC, ECL, Research, Immunoprecipitation, ELISA, Biology, A-DNA, SAN, W Ursae Majoris, Protein, Proteomics, Antibody, Vaccine, Lithium, Fine chemical, Aviva, Western blot

SAN DIEGO, April 11, 2022 /PRNewswire/ -- Aviva Systems Biology , a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its AvivaBlot product line of ECL reagents for western blot application.

Key Points: 
  • SAN DIEGO, April 11, 2022 /PRNewswire/ -- Aviva Systems Biology , a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its AvivaBlot product line of ECL reagents for western blot application.
  • To ensure researchers achieve the best from their western blots, the AvivaBlot ECL reagents are easy-to-use, high quality, and affordable for a variety of western blot detection needs.
  • "For nearly 20 years Aviva Systems Biology has supported customers with thousands of antibodies validated in Western Blot, the primary workhorse application for protein analysis in most research settings.
  • We are excited to now provide best-in-class ECL detection reagents that will support Aviva customers complete Western Blot workflow needs," said Kevin Harvey, Ph.D., President.

Bulfinch Leases 40,000 Square Feet to LabShares

Retrieved on: 
Thursday, December 9, 2021
Biotechnology, Science, Health, Other Science, Newton, SVP, HPLC, Biotechnology, QT, Massachusetts Turnpike, Safety, Restaurant, Labshare, I-95, CEO, Microscope, BSL2, Multimedia, List of highways numbered 128, Flow cytometry, The Bulfinch Companies, Coffee, Acquisition, SF, Western blot, Retail, Tunnel

The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and LabShares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge Park in Newton, Massachusetts, with an additional 25,000 square feet of space, bringing LabShares total leased premises at the complex to approximately 40,000 square feet.

Key Points: 
  • The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and LabShares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge Park in Newton, Massachusetts, with an additional 25,000 square feet of space, bringing LabShares total leased premises at the complex to approximately 40,000 square feet.
  • LabShares is a flexible, turnkey lab and coworking office space for life-science and biotech startups.
  • We are thrilled to support LabShares expansion at Chapel Bridge Park, stated Mike Wilcox, SVP, Director of Leasing at Bulfinch.
  • Bulfinch continues to expand our life science portfolio and seek partnerships with tenants like LabShares that help life science start-ups meet speed to market demands.

Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, December 2, 2021
Patient, Dystrophin, Myopathy, Heart, Security (finance), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Degenerative disease, DM1, Disease, Time, Private Securities Litigation Reform Act, Investigational New Drug, Form 10-Q, FORCE, Muscle, Dynamos, Clinical trial, IND, SEC, Securities and Exchange Commission (Philippines), Therapy, Male, COVID-19, MAD, Exon, DYN, Nasdaq, Twitter, Western blot, GLOBE, FSHD, Terminology, Â, Diaphragm, FDA, Mortality, Duchenne muscular dystrophy, LinkedIn, Facioscapulohumeral muscular dystrophy, PMO, Transferrin, Duchenne, DMD, Food, Pharmaceutical industry

WALTHAM, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.

Key Points: 
  • Planned endpoints include safety and tolerability, PK/PD, dystrophin expression as measured by Western Blot, and measures of muscle function.
  • In addition to DYNE-251, Dyne is building a DMD franchise with programs for patients with mutations amenable to skipping exons 53, 45 and 44.
  • DYNE-251 is Dynes therapeutic candidate being developed for people living with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
  • However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Bio-Techne Announces Commercial Release of Abby Automated Western System for Simple Western and Introduces Stellar Modules for Jess

Retrieved on: 
Thursday, April 8, 2021
Molecular biology, Branches of biology, Physical sciences, Natural sciences, Laboratory techniques, Blot, Western blot, Chemiluminescence, Fluorescence

In addition, ProteinSimple has announced the pending release of Stellar NIR and IR modules for Jess which will set a new industry standard for fluorescence Western blotting sensitivity.

Key Points: 
  • In addition, ProteinSimple has announced the pending release of Stellar NIR and IR modules for Jess which will set a new industry standard for fluorescence Western blotting sensitivity.
  • ProteinSimple's Simple Western systems are automated, hands-free, blot-free, Western platforms that deliver fully analyzed and quantitated results on 24 samples in as little as 3 hours.
  • The Stellar fluorescence modules for Jess provide low picogram sensitivity that is in the same range as Simple Western's unparalleled chemiluminescence detection.
  • Simple Western systems overcome the drawbacks of traditional western blots by providing automation, rapid time to quantitative results, and reproducibility.

Bio-Techne To Host Conference Call On August 4, 2020 To Announce Fourth Quarter 2020 Financial Results

Retrieved on: 
Monday, July 13, 2020
Branches of biology, Protein methods, Biology, Natural sciences, Omics, Proteomics, Western blot

The replay will be available from 11:00 a.m. CDT on Tuesday, August 4, 2020 until 11:00 p.m. CDT on Friday, September 4, 2020.

Key Points: 
  • The replay will be available from 11:00 a.m. CDT on Tuesday, August 4, 2020 until 11:00 p.m. CDT on Friday, September 4, 2020.
  • Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow.
  • These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.
  • With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has approximately 2,300 employees worldwide.

Rockland Develops Antibody Proven to Detect SARS-CoV-2 in Patient Samples

Retrieved on: 
Friday, May 29, 2020
Science, Biotechnology, Research, Other Manufacturing, Health, Infectious diseases, Genetics, Manufacturing, Branches of biology, Medical specialties, Biology, Immunologic tests, Laboratory techniques, Protein methods, Anatomical pathology, Pathology, ELISA, Immunofluorescence, Antibody, Western blot

Rockland Immunochemicals Inc. has developed a critical antibody reagent essential to antibody tests used to determine SARS-CoV-2 exposure for patients suspected to have contracted COVID-19 .

Key Points: 
  • Rockland Immunochemicals Inc. has developed a critical antibody reagent essential to antibody tests used to determine SARS-CoV-2 exposure for patients suspected to have contracted COVID-19 .
  • This antibody has proven effective in lateral flow assays (immunochromatography), ELISA, Western blotting, Immunofluorescence microscopy, fluorescence-activated cell sorting, and immunohistochemistry.
  • Dr. Carl Ascoli, Chief Science Officer for Rockland Immunochemicals Inc. stated that, This antibody is invaluable for the highly accurate detection of SARS-CoV-2 and subsequently COVID-19 disease in various types of patient samples, including nasal and throat swab extracts and saliva.
  • Rockland is currently in large scale production of this antibody for deployment in rapid tests that can be manufactured and distributed widely.